Biotechnology for the Non-Biotechnologist

Biotechnology for the Non Biotechnologist, ideal for non-Scientists and Scientists who need to understand the basic theory, principles, techniques, and potential of biotechnology.

22-24 Apr 2020

& 30 Sep-2 Oct 2020

GBP 1,849 1,549 *
EUR 2,589 2,169 *
USD 2,884 2,416 *
* When you book before 13 Mar

Book now

Course overview

This intensive three-day course is ideal for non-scientists and scientists needing to understand the basic theory, principles, techniques and potential of biotechnology.

Delegates will gain an overview of how biotech products are being developed and manufactured, and discuss the scientific and regulatory environment. The interactive programme will cover the latest advances in regulation, including biosimilars and advanced therapies, and address the role and importance of patents within biotech, including what actually can be patented.

Benefits of attending:

  • Gain an introduction to the fundamental principles of biotechnology
  • Improve your understanding of the key techniques used by biotechnologists
  • Understand tthe key regulatory considerations for biopharmaceuticals
  • Discuss advances in regulation – biosimilars and advanced therapies
  • Learn how to identify potential patents, and why and how they must be protected

Who should attend?

This course is ideal for anyone needing an overview or refresher, particularly those working in:

  • Quality assurance
  • Regulatory affairs
  • Legal and IP
  • Business development
  • Sales and marketing
  • Engineering
  • Finance
  • Clinical
  • Training
  • Project management

Programme day one

Introduction to biotechnology

  • Historical perspective
  • Diversity of biotechnology products
  • Impact on society
  • Product development overview

Introduction to molecular biology

  • DNA, RNA, genes, plasmids and vectors
  • Protein synthesis – transcription and translation

Re-expression of proteins

  • Recombinant DNA techniques
  • Monoclonal antibodies – from mouse to human
  • Transgenic animals and plants

Development of production organisms

  • Transfection
  • Selection
  • Preservation

Fermentation technology and large scale production

  • Types of fermenters
  • Fermentation basics
  • Modes of operation
  • Process development

General discussion session

Programme day two

Process optimisation and scale-up

  • Scale-up strategies
  • Strain improvement
  • Media improvement
  • Process improvement

Analysis of biopharmaceuticals

  • Biological activity
  • Physicochemical characterisation
  • Purity, impurities and contaminants

Product recovery and purification

  • Cell harvesting and removal
  • Clarification – intracellular and extracellular proteins
  • Chromatographic techniques

Formulation design of biopharmaceuticals

  • Factors affecting degradation
  • Choice of excipients
  • Prolonging shelf life

Process economics

  • Drug development and bioprocess economics
  • Optimising bioprocess economics
  • Manufacturing make or buy
  • Future manufacturing alternatives

General discussion session

Programme day three

Patenting biotech inventions

  • What is a patent?
  • What are the basic criteria for patentability?
  • What can be patented?
  • Can you patent genes, proteins, hybridomas, and stem cells?

Patent workshop

  • How to recognise what is patentable
  • Drafting claims to biotech inventions
  • Maximising protection for an invention
  • Understanding the examination process
  • Enforcing patents

Regulatory considerations of biopharmaceuticals

  • General principles
  • Product quality and control
  • Pre-clinical safety

Application of regulatory principles

  • What do regulators want?
  • Specifications
  • Product characterisation
  • Assessment of process change
  • Comparability guidance and strategy

Advances in regulation: biosimilars

  • Comparability, equivalence and biosimilarity
  • Biosimilars guidance
  • Guidance vs Practice – a case study

Advances in regulation: advanced therapies

  • Gene therapy
  • Cell therapy
  • Tissue engineered products

General discussion session


Mark Richardson

Mark Richardson is a Pharmaceutical/Biotech Drug Development Regulatory Affairs Consultant and is also Director of Richardson Associates Regulatory Affairs Ltd. After postdoctoral research in molecular biology at the Universities of Dundee and California at Berkeley, he joined British Biotech in 1988 to work on recombinant vaccines before becoming Head of Assay Development, then Biopharmaceutical Development Manager and subsequently moving into Regulatory Affairs with responsibility for rDNA products in preclinical and clinical development.

In 1997 he moved to Groupe Fournier as Head of the Gene Therapy Development Unit to lead a European oncology clinical development programme. Joining the CRO sector in 1999, first with Orion Clinical Services and later with i3 Research, he headed the Regulatory Affairs departments providing advisory and regulatory support for global development and clinical investigation of gene and cell therapy products, recombinant proteins and monoclonal antibodies, as well as for small molecule drugs.

Philip Webber

Dr. Philip Webber obtained his first degree from Cambridge University, UK (Natural Sciences, Genetics) and then carried out research on the regulation of brain-specific genes at Warwick University, UK, where he obtained his PhD.
He qualified as a UK Chartered Patent Attorney and European Patent Attorney with Dehns (formerly Frank B. Dehn & Co.) London and Oxford, and is now a partner in their Life Sciences Group. He has a worldwide client-base including clients from the UK, Scandinavia, the US and Japan. Amongst other things, his work involves the preparation and filing of patent applications in Europe and throughout the world; acting for his clients in opposition procedures at the European Patent Office; and searching for and advising his clients on the relevance of competitors’ patents. He is an active member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA). He has spoken at a number of European conferences and on BBC Radio on the patenting of biotech inventions, as well as publishing a number of papers in this area.

Alison Sykes

Alison Sykes is Director Physico-Chem Analytics, for Fresenius-Kabi, SwissBio Sim, a post she took up in 2017. She was formerly a Director within the Biosimilar Unit of Merch Serono and Biosimilar Technical Director within Analytical Services at Lonza Biologics plc responsible for oversight and definition of all analytical activities relating to pre-clinical and clinical development of Biosimilars derived from mammalian and microbial cell culture. She had worked for Lonza for 25 years, responsible for running various different analytical teams and functions including cell culture support, method development and validation, stability and formulation and protein characterisation. She has been responsible for set-up and establishing FDA and MHRA approved laboratories and providing technical and advisory support for CMC development of biopharmaceuticals from pre-clinical through to clinical phases, including several successful BLA licence applications. A biochemist by training, she started her career working for the National Health Service and then moved to NIBSC. Her experience here on the human side of the drug industry and the need for global standards in protein drug development helped drive her enthusiasm for detailed analysis and characterisation of safe and efficacious biopharmaceuticals.

Adekunle Onadipe

Dr Adekunle Onadipe is an Associate Research Fellow in Bioprocess R&D, Cell Line Development at Pfizer Inc. USA. He leads a group of scientists responsible for the construction, development and characterization of mammalian and microbial cell lines for biotherapeutics and vaccines production. His group is also involved in the scale-up of bioprocesses from bench top to pilot scale bioreactors and process development for the establishment of cell banks to support the manufacture of biopharmaceutical products for early phase clinical trials.

Kunle joined Pfizer Limited in the UK in 2005 in Discovery Biology with responsibility for optimizing cell culture processes for the production of cell-based assay reagents. Prior to this he worked for 15 years at Lonza Biologics plc., in Slough UK where, as a Principal Group Leader in cell culture process development, he was responsible for constructing and developing production mammalian cell lines and culture processes, subsequently transferring them to full-scale production for clinical trials.

A microbiologist by training, Kunle has been involved in the production of biopharmaceuticals for more than 30 years and has a broad experience of microbial and mammalian cell culture methods. He obtained his PhD in Microbiology from the University of Surrey, Guildford UK.

Adrian Haines

Dr Adrian Haines is the Section Head of Process Development Sciences at Novimmune SA, Switzerland. He leads teams of upstream and downstream development scientists who work within a CMC environment to develop, evaluate and characterise processes for the production of monoclonal antibodies and novel κλ-bodies. He has extensive experience in generating mammalian cell lines suitable for the GMP production of biologics.
He joined Novimmune in 2015 and prior to this he worked at Lonza Biologics in the UK working on projects to develop new technologies and processes for generating manufacturing cell lines. Before that he worked for ML Laboratories/Cobra Research developing UCOE technologies for the expression of proteins in mammalian cells and at Therexsys Ltd, developing antibody targeted gene therapies. Prior to this he worked at Celltech Research Ltd, generating radiolabelling and cross-linking technologies for antibodies.
A biochemist by training, he has been involved in the protein chemistry and production of monoclonal antibodies for over 28 years starting with his PhD where he generated monoclonal antibodies (using hybridoma technology) for the diagnosis of prostate cancer. He received his bachelor degree from Imperial College, London, and his PhD from St Thomas’ Hospital Medical School, University of London.

Peter O'Callaghan

Peter O’Callaghan holds BSc and PhD degrees in Genetics from Newcastle University. Since graduation he has gained over 10 years’experience in biotechnology research and development in academia and industry, during which time he co-authored patents as well as research articles and reviews in international peer-reviewed scientific journals and books.
Since 2011 he has been woking in the New Expression Technologies group at Lonza Biologics in Cambridge. He works as an Associate Principle Scientist where he leads efforts to develop new technologies for the industrial synthesis of antibody-based biotherapeutics.

Kate Smith

Kate Smith is currently Principal Scientist, Development Services, at BioReliance, UK, part of the Merck Group. In this position she is reponsible for providing technical supprt to both colleagues adn clients on the deign, execution and interpretation of viral clearance studies. Prior to transitioning into Development services Kate was responsible for managing the team involved in the preparatino of cell banks, viral seeds stocks and production of clinical lots of virus. .
Prior to joining BioReliance Kate was a Principal Group Leader in the Purification Development Group at Lonza Biologics, plc. She has more than 18 years experience in the development, scale-up, transfer and validation of purification processes for monoclonal antibodies and recombinant proteins from mammalian cell cultures. Her area of expertise is the design and management of Viral and DNA reduction studies used to support product safety.

Peter O'Callaghan

Book now

22-24 Apr 2020
22-24 Apr 2020 AC by Marriott Nice, Nice GBP 1,849.00
EUR 2,589.00
USD 2,884.00
+ VAT @ 20.00%
GBP 1,549.00
EUR 2,169.00
USD 2,416.00
Until 13 Mar*
Enrol now
30 Sep-2 Oct 2020
30 Sep-2 Oct 2020 Rembrandt Hotel, London GBP 1,849.00
EUR 2,589.00
USD 2,884.00
+ VAT @ 20.00%
Enrol now

* Note the early booking discount cannot be combined with any other offers or promotional code

You may also be interested in

Previous customers include...

  • Amgen Europe BV
  • Atlanpole
  • BD
  • BioFabri
  • Biosource Europe
  • Clinigen Group PLC
  • Covance
  • Ferring Pharmaceuticals A/S
  • Galderma
  • Genmab AS
  • Genmab B.V
  • Glaxo Smithkline Biologicals
  • GlaxoSmithKline
  • Kaesler Nutrition
  • Kinesis Pharma B.V.
  • Kings College London
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines and Healthcare Regulatory Agency
  • Merck Sharp & Dohme Ltd
  • Murex Biotech Ltd
  • Pfizer Limited
  • Sartorius Stedim Biotech
  • Stephen Griggs Ltd
  • Tarius A/S
  • Taylor Vinters
  • UCB Inc
  • University of Southampton
  • Vectura Group plc
  • Zacco Sweden AB

The content and presentation were very good

Rutger Vandiest, Sr Director - Head of Sales, Bavarian Nordic

I really appreciated the course and learned a lot.

Natacha Gonzalez, CMC Dossier & Compliance Specialist, Merck

For me - chemistry background, R&D and quality/regulatory on the job but all in small molecules - this course was perfect; content, presentations and speakers. My new job is all biologics and we outsource everything from R&D to production so really want to understand what is different from small mol's. Other delegates probably had a much tougher ride but I am very satisfied with this course.

Michael Vestling, Regulatory and Quality Manager, INTERVACC AB

The purpose of the meeting reached my goal

Gerda de Quillettes, Director, IT Infrastructure, Genmab B.V.

All fully achieved! Perfect!

Sergio Freitas, Development Program Lead, Tillotts Pharma AG

The course is prepared to explain biotechnology in a very clear and complete way. It is intensive and you have to be focused to follow, but it's definitely worth the effort!

Roza Puzio, European Projects Manager, Atlanpole

Excellent course - I learned a lot despite having worked as an inhouse-lawyer for a CMO for almost 5 years. The speakers where highly competent, engaged, knowledgable and able to answer all of my questions (and I had quite a few). Overall a course I can highly recommend to other inhouse lawyers.

Anna Damgaard Jensen, Head of Legal , AOP Orphan Pharma

Very good. Lot's of content. Thank you!

Falk Neukirch, CFO, Vita 34 AG

Interesting, dense, good quality speakers.

Anna Sarao, Regulatory Affairs Project Manager, Servier

Good selection. Good mix. This was useful for me.

Oliver Dale, Senior Specialist, MSD

Highly qualified speakers

Merecedes Rodríguez Rojas, Business Manager, CZ Veterinaria, S.A

All speakers were excellent and explained complex ideas very well. Fantastic, applicable course, presented really well. Great refresher course on Molecular biology.

Luisa Teixeira, Account Manager, Owen Mumford Ltd

Exciting world of journey into the Bio molecules. Well structured training, clear presentations and explanations.

Oliver Jungmann, Global Head Drug Substance Technical Lead, F. Hoffmann-La Roche Ltd.

Very good course, a bit condensed, very good speakers

Erik Andersen, Associate Director, Ferring Pharmaceuticals A/S

Very good

Rabiea Abdullah, Senior Regulatory Specialist, MSD

Course covers biopharmaceutical aspects of biotechnology thoroughly. Good presenters

Patrick John Couzens, Patent Attorney, Société des Produits Nestlé S.A.

Very positive opinion. Content very clear. Interaction with speakers was fruitful. Good to have each day a summary of what was learnt the day before.

Vanessa Brousset, Manager Europe, Galderma R&D

Very good. Broad overview. Friendly audience

Jean-Paul Chappuis, Galderma International

Speakers - well experienced. Content - well structured presentations

Lina Cacic, Regulatory Affairs Advisor, Agency for Medicinal Products and Medical Devices of Croatia (HALMED)

An excellent course! Very informative both for beginners and as a refresher.

Sarah Norton, Senior Scientific Officer, Veterinary Medicines Directorate

Course was very well outlined, prepared and presented

Isaac Hanania, LL.M., Boehringer Ingelheim RCV GmbH & Co KG

Very well organised

Marjon van Dijk, Associate Consultant Chemistry, Manufacturing & Control, Kinesis Pharma B.V

I really enjoyed this course, it was detailed and interesting. Speakers were very well qualified and good presenters.

Jill Challis, Principal Consultant, NDA Regulatory Science Ltd

Intense but very interesting course that takes you back to the basis of biotechnology and also provides some inside in regulations

An van Hemelrijck, RA Consultant, PhaRA

Good, useful, complicated

Nicolai Soberg-Hansen, Patent Administrator, Genmab A/S

Very comprehensive and intense. Mostly interested in the science and processes, less interested in patents.

David Cooke, Analytical Science Team Leader, Pfizer Ltd

I liked the course and would recommend this to work colleagues

Anna Woźniak, Valeant Sp. z o.o. Sp. j.